Chemotherapy complications (chemotherapy-induced nausea & vomiting, oral mucositis, vesicant extravasation, anthracycline cardiotoxicity)
Oncology therapy complication · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Common non-neutropenic chemotherapy toxicities presenting to ED. Covers chemotherapy-induced nausea/vomiting (CINV), mucositis, vesicant extravasation (a time-critical injury), and anthracycline/HER2 cardiotoxicity. (Febrile neutropenia and tumour lysis have separate protocols.) Always confirm regimen, cycle day and last dose.
Red flags
- Fever/neutropenia in any chemo patient (treat as sepsis)
- Vesicant extravasation (anthracycline, vinca) - tissue-necrosing emergency
- Intractable vomiting with dehydration/AKI/electrolyte derangement
- New heart failure, arrhythmia or chest pain (cardiotoxicity/ACS)
- Mucositis preventing oral intake (dehydration, infection portal)
Assessment
Differential diagnosis
- Bowel obstruction / constipation / raised ICP (for vomiting)
- Neutropenic sepsis (parallel consideration in any unwell chemo patient)
- Infective mucositis (candida, HSV)
- Cellulitis/abscess vs extravasation at cannula site
- Cardiac: ACS, PE, fluid overload (for cardiotoxicity)
Investigations
- FBC (always exclude neutropenia), U&E (dehydration/AKI from vomiting), glucose, calcium
- Document chemotherapy agent(s), emetogenic risk, cycle day
- For extravasation: identify the drug (vesicant vs irritant), examine site, mark area, photograph
- For cardiotoxicity: ECG, troponin, BNP, echocardiogram (LVEF) - compare with baseline
- Mucositis: assess severity (WHO grade), swabs if infection suspected, hydration/nutrition status
Management
- ALWAYS check for neutropenia/sepsis in any unwell chemotherapy patient first
- CINV: rehydrate, give antiemetics by emetogenic risk (5-HT3 antagonist + dexamethasone +/- NK1 antagonist for highly emetogenic; add metoclopramide/olanzapine for breakthrough)
- EXTRAVASATION (vesicant e.g. anthracyclines, vinca alkaloids): STOP infusion immediately, do NOT flush, aspirate residual drug via cannula, remove cannula, elevate limb
- Extravasation antidote/thermal measures by drug: anthracycline - cold compress + dexrazoxane; vinca alkaloids - WARM compress + hyaluronidase; urgent oncology/plastics referral
- Mucositis: analgesia (topical + systemic/opioid), oral hygiene/saline rinses, antifungal/antiviral if infected, maintain hydration/nutrition, admit if unable to swallow/dehydrated
- Cardiotoxicity: manage heart failure per standard pathway, hold cardiotoxic agent, urgent cardio-oncology/echo
- Liaise with the patient's oncology team for all significant toxicity and dose modification
Drugs & doses
Ondansetron 8 mg IV/PO twice daily (CINV; caution QT) [verify local dose]
Dexamethasone 8-12 mg IV/PO once daily (antiemetic adjunct) [verify local dose]
Aprepitant 125 mg PO day 1 then 80 mg daily (NK1 antagonist, highly emetogenic regimens) [verify local dose]
Metoclopramide 10 mg IV/PO three times daily or olanzapine 5-10 mg PO once daily for breakthrough nausea [verify local dose]
Dexrazoxane IV within 6 h for anthracycline extravasation (specialist) [verify local dose]
Hyaluronidase SC around site for vinca alkaloid extravasation [verify local dose]
Topical analgesia (e.g. benzydamine/lidocaine mouthwash) + systemic opioids for mucositis [verify local dose]
Standard heart-failure therapy (ACE-i/beta-blocker/diuretic) for anthracycline cardiomyopathy [verify local dose]
Disposition
Extravasation/cardiotoxicity/severe mucositis/intractable CINV -> admit or urgent oncology review. Mild controlled symptoms -> discharge with antiemetics, oral care and oncology follow-up. Any neutropenic sepsis -> admit per that protocol.
Complications & pitfalls
- Dehydration, AKI, electrolyte disturbance from CINV
- Tissue necrosis / ulceration requiring debridement from extravasation
- Secondary infection / sepsis via mucosal breakdown
- Irreversible cardiomyopathy (anthracyclines, trastuzumab)
- Malnutrition and treatment delay
Exam pearls
- The first question for any sick chemo patient is: are they neutropenic/septic? Treat that in parallel
- Extravasation of a vesicant is time-critical: STOP, aspirate (do not flush), then drug-specific measure - COLD + dexrazoxane for anthracyclines, WARM + hyaluronidase for vinca alkaloids
- Match antiemetics to the regimen's emetogenic risk; olanzapine is excellent for refractory CINV
- Anthracycline cardiotoxicity can be delayed by years - take a chemo history in any new cardiomyopathy
- Always involve the patient's oncology team - toxicities drive dose adjustments
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.